The content on this site is intended for healthcare professionals only
Prof Christopher Fox speaks to ecancer about results from the phase 3 EPCORE DLBCL-1 trial comparing epcoritamab monotherapy with investigator’s choice chemoimmunotherapy in patients with relapsed or refractory large B-cell lymphoma.
He reports that epcoritamab significantly improved progression-free survival and achieved higher complete response rates than standard chemoimmunotherapy. Responses were also more durable, with patients experiencing substantially longer durations of response and requiring fewer subsequent treatments.
Dr Fox explains that overall survival was not significantly different between the treatment groups, although interpretation was complicated by COVID-19-related mortality and the use of subsequent therapies such as CAR-T cells and other bispecific antibodies.
First-in-human study of in vivo CAR-T therapy shows promising activity in relapsed or refractory B-cell non-Hodgkin lymphoma
Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma
Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicular lymphoma
Lack of benefit of auto-HCT in MCL patients in first complete remission with undetectable MRD
Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM
Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in RR LBCL
Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of CLL
Pembrolizumab after chemo demonstrates promising activity in low-risk cHL
Impact of MRD on progression-free survival in MM patients treated with isatuximab, lenalidomide, bortezomib and dexamethasone
